Shibuya N, Yoshida J, Kobayashi T, Kageyama N
No Shinkei Geka. 1983 Apr;11(4):361-7.
In vitro sensitivity test of cultured human malignant glioma cells to ACNU[1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride] was performed on Falcon 3064 microtestplate. Early culture cells established from 10 clinical cases were examined by means of this method and the correlation between in vitro response and clinical response of tumor to ACNU was studied. In microtestplate assay, it was defined as ACNU sensitive when the tumor growth showed more than 60% suppression when tumor was cultured in the medium which contained 40 meg/ml of ACNU. Clinical responses were evaluated by means of CT scan, being divided into 4 classes, PR (partial response), CR (complete response), NC (no change) and PD (progressive disease). The former two groups were regarded as responder and the latter two as nonresponder. The correlationship between in vitro response and clinical response was higher in resistant group (100%) than in the sensitive group (60%), so the resistant tumor can be checked with this method. For this reason, the use of this assay may prove helpful in the selection of the chemotherapeutic agents.
在Falcon 3064微量试验板上对培养的人恶性胶质瘤细胞进行了对ACNU[1-(4-氨基-2-甲基-5-嘧啶基)甲基-3-(2-氯乙基)-3-亚硝基脲盐酸盐]的体外敏感性试验。用该方法检测了从10例临床病例中建立的早期培养细胞,并研究了肿瘤对ACNU的体外反应与临床反应之间的相关性。在微量试验板分析中,当肿瘤在含有40微克/毫升ACNU的培养基中培养时,肿瘤生长抑制率超过60%,则定义为对ACNU敏感。通过CT扫描评估临床反应,分为4类,PR(部分缓解)、CR(完全缓解)、NC(无变化)和PD(疾病进展)。前两组被视为反应者,后两组为无反应者。耐药组的体外反应与临床反应之间的相关性(100%)高于敏感组(60%),因此该方法可用于检测耐药肿瘤。因此,该试验的应用可能有助于化疗药物的选择。